Hormonal Prevention of Menstrual Migraine
For reproductive-age women with menstrual migraine who fail optimized acute therapy, initiate perimenstrual prophylaxis with either a long-acting NSAID (naproxen) or a long-acting triptan (frovatriptan 2.5 mg twice daily or naratriptan 1 mg twice daily) for 5 days, starting 2 days before expected menstruation. 1
First-Line Perimenstrual Prophylaxis
The most evidence-based approach for menstrual migraine prevention involves short-term prophylaxis timed to the vulnerable perimenstrual window:
- Frovatriptan 2.5 mg twice daily (Grade B evidence) 2
- Naratriptan 1 mg twice daily (Grade B evidence) 2
- Naproxen (long-acting NSAID formulation) 1
These medications should be taken for 5 consecutive days, beginning 2 days before the anticipated first day of menstruation 1. This targeted approach is particularly effective for the approximately 8% of women with pure menstrual migraine (attacks exclusively related to menstruation) 1.
Hormonal Contraceptive Options
For Women WITHOUT Aura
Continuous combined hormonal contraceptives (CHCs) are an appropriate option for women with menstrual migraine without aura who also need contraception 1. The key is avoiding estrogen withdrawal:
- 24/4 regimen (24 active pills + 4 placebo) is superior to traditional 21/7 regimens, significantly reducing both intensity and duration of menstrual migraine 3
- Continuous use without any placebo break eliminates the estrogen withdrawal trigger entirely 1, 4
- Ultra-low-dose formulations (<20 μg ethinyl estradiol) in continuous regimens may help prevent attacks 5
The 24/4 regimen with ethinyl estradiol 20 μg/drospirenone 3 mg demonstrated significantly better outcomes than 21/7 regimens in reducing menstrual migraine intensity and duration 3.
Critical Contraindication
Combined hormonal contraceptives are absolutely contraindicated in women with migraine with aura, regardless of menstrual association, due to increased stroke risk 1. For these women, consider:
- Progestogen-only contraceptives (safe alternative)
- Optional addition of transdermal estrogen to progestogen-only regimens 6
Transdermal Estrogen Supplementation
Transcutaneous estradiol 1.5 mg applied perimenstrually has Grade B evidence for efficacy 2. This approach supplements declining estrogen levels during the vulnerable perimenstrual period without the stroke risk associated with combined oral contraceptives in women with aura.
Treatment Algorithm
- Optimize acute treatment first - Ensure effective abortive therapy is in place
- If acute therapy insufficient:
- Start perimenstrual prophylaxis with frovatriptan, naratriptan, or naproxen
- Timing: 5 days starting 2 days before menses
- If contraception also needed:
- Without aura: Continuous CHC (24/4 or no break) with ≤20 μg ethinyl estradiol
- With aura: Progestogen-only method ± transdermal estrogen
- Consider transdermal estradiol 1.5 mg as alternative perimenstrual prophylaxis
Important Caveats
Avoid cyclical hormone preparations - These perpetuate estrogen withdrawal and can worsen menstrual migraine 6. The estrogen drop during placebo weeks is the primary trigger.
Perimenopause requires different management - During early perimenopause, hyperestrogenism and fluctuating levels make menopause hormone therapy (MHT) problematic and often worsens migraine 6. Hormone cycle control with continuous CHC (if no aura) or progestogen-only regimens is more appropriate than MHT during this phase 6.
Document attack timing - Use headache diaries for at least 3 menstrual cycles to confirm the menstrual relationship before initiating hormone-based prevention 1.
Recent evidence on CGRP antibodies - While CGRP monoclonal antibodies (erenumab, galcanezumab) show effectiveness in reducing monthly headache days for menstrual migraine 7, they represent third-line preventive options per current guidelines 8 and should be reserved for patients who fail first-line perimenstrual prophylaxis and standard preventive medications.